Australia markets open in 5 hours 7 minutes

Alnylam Pharmaceuticals, Inc. (0HD2.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
285.14+2.04 (+0.72%)
At close: 06:26PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.38
52-week change 3-18.85%
S&P500 52-week change 332.96%
52-week high 3285.16
52-week low 3143.66
50-day moving average 3170.73
200-day moving average 3180.79

Share statistics

Avg vol (3-month) 31.44k
Avg vol (10-day) 3346
Shares outstanding 5101.03M
Implied shares outstanding 6N/A
Float 8127.84M
% held by insiders 10.42%
% held by institutions 196.07%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin -3.11%
Operating margin (ttm)7.37%

Management effectiveness

Return on assets (ttm)1.73%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)2.34B
Revenue per share (ttm)18.62
Quarterly revenue growth (yoy)107.00%
Gross profit (ttm)N/A
EBITDA 157.97M
Net income avi to common (ttm)-72.94M
Diluted EPS (ttm)-7.49
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.62B
Total cash per share (mrq)20.44
Total debt (mrq)2.71B
Total debt/equity (mrq)N/A
Current ratio (mrq)3.01
Book value per share (mrq)-0.02

Cash flow statement

Operating cash flow (ttm)372.26M
Levered free cash flow (ttm)424.34M